Program
cebranopadol
Also written as “GRT6005”, “Cebranopadol” and “Cebranopadol 600 µg”.
Its studies are mostly in Pain · Chronic Pain · Acute Pain · Substance-Related Disorders · Osteoarthritis, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Tris Pharma | 160 open or running | phase 3since Oct 7, 2013 | Mar 24, 2009 | none ahead |
| Adneuris Therapeutics | 22 open or running | phase 3since Sep 22, 2026 | Sep 22, 2026 | Jan 2027phase 3 · NCT07845071 |
Also a collaborator on its studies: AbbVie.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 4 studies since Mar 24, 2009.
- Oct 16, 2012Phase 2 study in OsteoarthritisTris Pharma · NCT01709214 · 619 enrolled · United States
- Nov 8, 2012Phase 2 study in Low Back PainTris Pharma · NCT01725087 · 1,089 enrolled · Austria, Belgium, Denmark and more
- Sep 6, 2013Phase 2 study in Chronic PainTris Pharma · NCT01939366 · 699 enrolled · United States, Austria, Denmark and more
- Oct 7, 2013Phase 3 study in PainTris Pharma · NCT01964378 · 200 enrolled · Austria, Belgium, Bulgaria and more
- Dec 12, 2013Phase 3 study in PainTris Pharma · NCT02031432 · 76 enrolled · Austria, Belgium, Bulgaria and more
- Mar 18, 2019Phase 1 study in PharmacokineticTris Pharma · NCT03882762 · 34 enrolled · United States
- May 20, 2019Phase 1 study in Prolonged QTc IntervalTris Pharma · NCT03958123 · 171 enrolled · United States
- Feb 16, 2022Phase 1 study in PainTris Pharma · NCT05256108 · 38 enrolled · United States
- Jul 27, 2022Phase 1 study in PainTris Pharma · NCT05491785 · 30 enrolled · Netherlands
- May 16, 2024Phase 3 study in Acute PainTris Pharma · NCT06423703 · 240 enrolled · United States
- Jun 5, 2024Phase 1 study in Substance-Related DisordersTris Pharma · NCT06453265 · 48 enrolled · United States
- Aug 6, 2024Phase 3 study in Acute PainTris Pharma · NCT06545097 · 279 enrolled · United States
- Sep 22, 2026Adneuris Therapeutics's first study: phase 3 study in PainNew to Adneuris TherapeuticsAdneuris Therapeutics · NCT07845071 · 160 planned · United States
- Oct 8, 2026Phase 2 study in Chronic PainAdneuris Therapeutics · NCT07874620 · 45 planned · United States
Ahead
- Jan 2027Primary completion: phase 3 study in PainAdneuris Therapeutics · NCT07845071
- Mar 2027Primary completion: phase 2 study in Chronic PainAdneuris Therapeutics · NCT07874620
TargetBeta
“An orally available benzenoid that acts as an opioid peptide receptor agonist for the nociceptin/orphanin FQ peptide receptor (opioid receptor like -1; OPRL1; ORL-1; NOP; kappa-type 3 opioid receptor) and the classical opioid receptors, mu, delta and kappa, ”NCIt, by rule
“Nociceptin receptor agonist; Opioid receptors; mu/kappa/delta agonist”ChEMBL 37, by rule
Studies
All 18 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07874620Chronic Pain · United States | 2 | Recruiting | Adneuris Therapeutics | Mar 2027 | 45 |
| NCT07845071Pain · United States | 3 | Recruiting | Adneuris Therapeutics | Jan 2027 | 160 |
| NCT06545097Acute Pain · United States | 3 | Completed | Tris Pharma | Dec 30, 2024 | 279 |
| NCT06453265Substance-Related Disorders · United States | 1 | Completed | Tris Pharma | Nov 6, 2024 | 48 |
| NCT06423703Acute Pain · United States | 3 | Completed | Tris Pharma | Jan 31, 2025 | 240 |
| NCT05491785Pain · Netherlands | 1 | Completed | Tris Pharma | Mar 30, 2023 | 30 |
| NCT05256108Pain · United States | 1 | Completed | Tris Pharma | Jul 12, 2022 | 38 |
| NCT03958123Prolonged QTc Interval · United States | 1 | Completed | Tris Pharma | Nov 27, 2013 | 171 |
| NCT03882762Pharmacokinetic · United States | 1 | Completed | Tris Pharma | Sep 17, 2014 | 34 |
| NCT02031432Pain · Austria, Belgium, Bulgaria and more | 3 | Completed | Tris Pharma | Apr 2016 | 76 |
| NCT01964378Pain · Austria, Belgium, Bulgaria and more | 3 | Terminated | Tris Pharma | Oct 16, 2015 | 200 |
| NCT01939366Chronic Pain · United States, Austria, Denmark and more | 2 | Completed | Tris Pharma | Jan 2015 | 699 |
| NCT01725087Low Back Pain · Austria, Belgium, Denmark and more | 2 | Completed | Tris Pharma | Jul 2014 | 1,089 |
| NCT01709214Osteoarthritis · United States | 2 | Completed | Tris Pharma | Apr 2014 | 619 |
| NCT01357837Osteoarthritis, Knee · Austria, Poland, Spain | 2 | Completed | Tris Pharma | Dec 2011 | 207 |
| NCT01347671Pain · Bulgaria, Germany, Romania | 2 | Completed | Tris Pharma | Jan 2012 | 189 |
| NCT00878293Diabetic Neuropathies · Germany, United Kingdom | 2 | Completed | Tris Pharma | May 2010 | 90 |
| NCT00872885Pain, Postoperative · United States | 2 | Completed | Tris Pharma | Aug 2009 | 258 |
How it is read
Names in the registry
- “GRT6005”, 8 entries
- “Cebranopadol”, 5 entries
- “Cebranopadol 600 µg”, 3 entries
- “Cebranopadol 400 ug”, 2 entries
- “Cebranopadol 1000 µg”, 2 entries
Conditions, from the studies’ own filings
- Pain, 5 studies
- Chronic Pain, 3 studies
- Acute Pain, 2 studies
- Substance-Related Disorders, 1 study
- Osteoarthritis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.